We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

36 hedge funds and large institutions have $32.6M invested in BioXcel Therapeutics in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

80% more funds holding

Funds holding: 20 → 36 (+16)

31% more capital invested

Capital invested by funds: $24.9M → $32.6M (+$7.64M)

0.19% more ownership

Funds ownership: 1% → 1.2% (+0.19%)

Holders
36
Holders Change
+16
Holders Change %
+80%
% of All Funds
0.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
10
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.02M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$857K
3
State Street
State Street
Massachusetts
+$679K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$372K
5
Squarepoint
Squarepoint
New York
+$340K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.42M
2
Creative Planning
Creative Planning
Kansas
-$154K
3
Millennium Management
Millennium Management
New York
-$127K
4
Morgan Stanley
Morgan Stanley
New York
-$25.6K
5
Bank of America
Bank of America
North Carolina
-$9.49K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
1
Artemis Investment Management
United Kingdom
$10.6M +$106K +627 +1%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$7.75M -$1.42M -8,404 -16%
BlackRock
3
BlackRock
New York
$3.28M +$3.02M +17,802 +1,989%
California Public Employees Retirement System
4
California Public Employees Retirement System
California
$3.27M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.84M +$857K +5,060 +45%
UBS Group
6
UBS Group
Switzerland
$828K +$5.08K +30 +0.6%
Renaissance Technologies
7
Renaissance Technologies
New York
$785K +$284K +1,675 +60%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$662K +$372K +2,194 +139%
State Street
9
State Street
Massachusetts
$526K +$679K +4,009 New
Northern Trust
10
Northern Trust
Illinois
$481K +$330K +1,951 +248%
Squarepoint
11
Squarepoint
New York
$352K +$340K +2,010 New
Bank of New York Mellon
12
Bank of New York Mellon
New York
$198K +$191K +1,130 New
Creative Planning
13
Creative Planning
Kansas
$175K -$154K -909 -48%
Charles Schwab
14
Charles Schwab
California
$138K +$133K +784 New
N
15
Nuveen
North Carolina
$117K +$113K +668 New
California State Teachers Retirement System (CalSTRS)
16
California State Teachers Retirement System (CalSTRS)
California
$102K +$98.2K +580 New
New York State Common Retirement Fund
17
New York State Common Retirement Fund
New York
$101K +$97.4K +575 New
CIAS
18
Capital Investment Advisory Services
North Carolina
$53K +$53K +313 New
Deutsche Bank
19
Deutsche Bank
Germany
$49K +$48.1K +284 New
Barclays
20
Barclays
United Kingdom
$43K +$41.2K +243 New
AIG
21
American International Group
New York
$42K +$40.7K +240 New
AWM
22
AllSquare Wealth Management
New York
$19K – – –
Bank of Montreal
23
Bank of Montreal
Ontario, Canada
$19K +$5.25K +31 +41%
Citigroup
24
Citigroup
New York
$18K +$1.02K +6 +6%
JP Morgan Chase
25
JP Morgan Chase
New York
$18K +$17.6K +104 New
1
2

BTAI Hedge Fund Activity: Q2 2019 in Review

36 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2019, worth a combined $32.6M — up 31% from $24.9M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new BTAI positions and 2 closed out — a net gain of 16 holders — while 10 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $3.02M. The largest seller was Fidelity Investments, cutting an estimated $1.42M.

  • 36 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2019, up from 20 in Q1 2019.
  • Funds reported $32.6M of BioXcel Therapeutics stock for Q2 2019, up 31% quarter-over-quarter.
  • 18 funds opened new BioXcel Therapeutics positions in Q2 2019 and 2 closed out, a net change of +16 holders.
  • The largest BioXcel Therapeutics buyer in Q2 2019 was BlackRock, an estimated $3.02M added.
  • The largest BioXcel Therapeutics seller in Q2 2019 was Fidelity Investments, an estimated $1.42M sold.

Based on aggregated 13F filings for Q2 2019.